Search Results - "Balske, A."

Treatment of postmenopausal osteoporosis with delayed-release risedronate 35 mg weekly for 2 years by McClung, M. R., Balske, A., Burgio, D. E., Wenderoth, D., Recker, R. R.

“…Summary Bone mineral density response to once weekly delayed-release formulation of risedronate, given before or following breakfast, was non-inferior to that…”
Get full text

The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis by Brown, J P, Kendler, D L, McClung, M R, Emkey, R D, Adachi, J D, Bolognese, M A, Li, Z, Balske, A, Lindsay, R

“…This study evaluated the efficacy and tolerability of risedronate once a week (35 mg and 50 mg) compared with risedronate 5 mg once daily in women with…”
Get full text

Efficacy and safety of a novel delayed-release risedronate 35 mg once-a-week tablet by McClung, M. R., Miller, P. D., Brown, J. P., Zanchetta, J., Bolognese, M. A., Benhamou, C. L., Balske, A., Burgio, D. E., Sarley, J., McCullough, L. K., Recker, R. R.

“…Summary Dosing regimens of oral bisphosphonates are inconvenient and contribute to poor compliance. The bone mineral density response to a once weekly…”
Get full text

Prevention of Bone Loss with Alendronate in Postmenopausal Women under 60 Years of Age by Hosking, David, Chilvers, Clair E.D, Christiansen, Claus, Ravn, Pernille, Wasnich, Richard, Ross, Philip, McClung, Michael, Balske, Ana, Thompson, Desmond, Daley, Marianne, Yates, A. John

“…Osteoporosis is a common and important cause of morbidity and mortality among postmenopausal women. 1 – 3 It arises as a consequence of progressive loss of…”
Get full text

Alendronate and estrogen-progestin in the long-term prevention of bone loss: four-year results from the early postmenopausal intervention cohort study. A randomized, controlled trial by Ravn, P, Bidstrup, M, Wasnich, R D, Davis, J W, McClung, M R, Balske, A, Coupland, C, Sahota, O, Kaur, A, Daley, M, Cizza, G

“…Up to 3 years of treatment with alendronate, 5 mg/d, prevents postmenopausal bone loss. To determine whether the effect of alendronate is sustained at 4 years…”
Get full text

Alendronate and estrogen-progestin in the long-term prevention of bone loss : Four-year results from the early postmenopausal intervention cohort study: A randomized, controlled trial by RAVN, P, BIDSTRUP, M, CIZZA, G, WASNICH, R. D, DAVIS, J. W, MCCLUNG, M. R, BALSKE, A, COUPLAND, C, SAHOTA, O, KAUR, A, DALEY, M

Get full text

Clinical Investigations: The Ecacy and Tolerability of Risedronate Once a Week for the Treatment of Postmenopausal Osteoporosis by Brown, J P, Kendler, D L, McClung, M R, Emkey, R D, Adachi, J D, Bolognese, M A, Z. Li, Balske, A, Lindsay, R

Get full text

Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group by Hosking, D, Chilvers, C E, Christiansen, C, Ravn, P, Wasnich, R, Ross, P, McClung, M, Balske, A, Thompson, D, Daley, M, Yates, A J

“…Estrogen-replacement therapy prevents osteoporosis in postmenopausal women by inhibiting bone resorption, but the balance between its long-term risks and…”
Get full text